Advanced Filters
noise

solid-tumors Clinical Trials

A listing of solid-tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,625 clinical trials
H Huan Zhou

TR64 in Patients With Advanced Solid Tumors

This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when administered qd in patients with advanced solid tumors. Up to 6 cohorts of 1-6 or 3-6 patients each will be treated in …

18 - 75 years of age All Phase 1
S Sud Agarwal

Sapu003 in Advanced mTOR-sensitive Solid Tumors

This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative breast cancer, renal cell carcinoma \[RCC\], neuroendocrine tumors \[NETs\], tuberous sclerosis complex \[TSC\]-associated tumors, and hepatocellular carcinoma \[HCC\]).

18 years of age All Phase 1
S Shuxian An

Trop2-targeted immunoPET Imaging of Solid Tumors

This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung …

18 - 75 years of age All Phase 2/3
T Tong Xiangmin, Ph.D

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

This is an investigator-initiated trial aimed at evaluating the safety and preliminary efficacy of a novel red blood cell-based therapy, where engineered red blood cells are conjugated with checkpoint inhibitors.

18 - 75 years of age All Phase 0
C Caicun Zhou, PhD

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.

18 years of age All Phase 1/2
X Xiaohong Han

A Study of BPI-460372 in Advanced Solid Tumor Patients

This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.

18 years of age All Phase 1
B Binghe Xu

A Study of EOC237 in Patients With Advanced Solid Tumor

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

18 - 75 years of age All Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.

3 - 30 years of age All Phase 1
G GV20 Therapeutics

Study of GV20-0251 in Participants With Solid Tumor Malignancies

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

18 years of age All Phase 1/2
P Paul Vasey

HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies

The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044. HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) …

18 - 75 years of age All Phase 1/2

Simplify language using AI